

[No Images? Click here](#)

Newsletter - October 2016

The latest update on all things Reapplix...

Hello!! Summer is over and we now head into the Autumn months, with plenty of planned activities to provide an exciting close to 2016.

Despite the Summer break, there has still been plenty of activity as we have been busy successfully raising new capital, getting ready to fund a new independent clinical study, building significant user traction at clinics in Germany outside our clinical trial work, adding a new publication to our list and recruiting a new member to the team. Please read on for more news on these exciting topics.

Thanks for your continued interest and support.

Did you know?

Over 5,000 LeucoPatch® devices have been used so far to treat patients.

Over 400 patients have been treated outside of (and in addition to) our clinical trials.

New multi-centre clinical trial to evaluate LeucoPatch® in the treatment of malleoli ulcers

Reapplix has announced that it is funding a new clinical study for LeucoPatch®, on the healing of ulcers on the malleoli, a bony prominence on the ankle, which are often very hard-to-heal, due to the thin layer of tissue over this area.

LeucoPatch® improves wound healing by concentrating cells and growth factors from the patient's own blood and applying them to their wounds. Through this, LeucoPatch® is able to accelerate healing and improve clinical outcomes.

The LiDMUS (LeucoPatch® in Diabetic Malleoli Ulcer Study) study will evaluate both the effect of LeucoPatch® on wound healing and the effect on the local wound environment.

Following encouraging results from a continuing case series by Dr Magnus Löndahl in Lund, Sweden, Reaplix will fund this new 36 patient LiDMUS Randomized Controlled Trial to assess multiple endpoints, including ulcer healing frequency, time to healing and area reduction. Wound and blood samples collected as part of the study will be analysed to confirm the mode-of-action of LeucoPatch® and further advance the scientific documentation.

The trial will be run independently by the Sponsor, Dr Magnus Löndahl, from Skåne University Hospital, Lund, Sweden and will recruit patients at centres in both Sweden and Denmark. Nordsjællands Hospital Department of Clinical Research will be the CRO for the study.

This new study is in addition to the 250 patient diabetic foot ulcer Randomized Controlled Trial that is being conducted in UK, Sweden and Denmark, which expects to report results in 2017.

Rasmus Lundquist (CSO) commented: *"A key goal of Reaplix is to add to the understanding of wound healing in general and the effects of LeucoPatch® on chronic wounds specifically. Analysis of patient derived LeucoPatches and wound samples will give us great insights into the involvement of the applied leucocytes and cytokines in the transition of these very chronic wounds into healing ones. Key features are believed to be the transition of macrophages from the pro-inflammatory M1 type to the tissue-healing M2 phenotype and the involvement of LeucoPatch® derived stem cells in the healing process."*

Graeme Brookes, Chief Executive Officer at Reaplix, added: *"Malleoli ulcers are difficult to treat and to heal, therefore we welcome the opportunity to test LeucoPatch® on these hard-to-heal wounds to prove that*

we can provide an efficacious treatment that can both reduce healthcare costs and improve patient outcomes.”



The LiDMUS logo !

Did you know?

'Mus' means 'Mouse' in Danish

Reapplix confirms new funds raised

Reapplix has successfully closed a new funding round of €2.8 million. This new funding was provided by the existing investors, Seed Capital, Novo SEEDS and Vækstfonden (The Danish Growth Fund).

The new funding will be used to provide continuing forward momentum to the final stages of pre-revenue value creation through to 2018, when Reapplix intends to raise further growth capital in order to undertake the full commercial launch of its lead product, LeucoPatch®.


Graeme Brookes, Chief Executive Officer at Reapplix, commented on the news: *“Having completed the product development and obtained regulatory clearance in both Europe and USA, we are now awaiting the completion in 2017 of our large scale randomized controlled trial, which will be key to gaining reimbursement. This new funding allows us to continue to invest in clinical evidence and in product enhancements in parallel with our work building commercial proof of principle”*

The new guy!

We are very pleased to be able to announce that we are strengthening the team with the addition of Jonas

Damgård Schmidt, reporting to our CSO, Rasmus Lundquist.

Jonas finalized his PhD in skin immunology recently and will work as an Industrial PostDoc at Reapplix. Research will focus on the cellular and molecular mode of action of the LeucoPatch® in chronic wounds. Key features are the immune status of the wound and the changes induced by applying a LeucoPatch®. The work will be done in cooperation with Associate Professor Charlotte Menne Bonefeld and the Institute of Immunology and Microbiology at the University of Copenhagen. We are very excited about the opportunity to learn even more about the basis of the clinical effects seen when treating wounds with LeucoPatch®.



New publication

A new book has been published: 'Wound Healing Biomaterials', edited by Professor Magnus Ågren (University of Copenhagen). This features a full chapter on LeucoPatch® entitled 'Autologous cell-rich biomaterial (LeucoPatch) in the treatment of diabetic foot ulcers'

Conference season is upon us!

As is usual at this time of the year,
the conference calendar is very busy. Here is the list
of conferences attended and those which we will
visit, please do seek us out and say hello:

DFSG (Diabetic Foot Study Group); Stuttgart, Germany,
9-11 September 2016

WUWHS (World Union Wound Healing Societies);
Florence, Italy, 26-28 September 2016

SAWC Fall (Symposium Advanced Wound Care); Las
Vegas, USA, 6-9 October 2016

AdvaMed, Minneapolis, USA, 16-19 October 2016

Wounds UK; Harrogate; United Kingdom, 14-15
November 2016

Innovations in Wound Healing, Key Largo, Florida, USA,
8-11 December 2016

Please do contact us with any questions you
have or just to find out more!

Anette Walther Mørck - Clinical Research
Associate [+4560434299](tel:+4560434299) awm@reapplix.com

Rasmus Lundquist - Chief Scientific Officer [+4526717447](tel:+4526717447)
rl@reapplix.com

Niels Erik Holm - Chief Operating Officer [+4526221962](tel:+4526221962)
neh@reapplix.com

Graeme Brookes - Chief Executive Officer [+4553777447](tel:+4553777447)
gnb@reapplix.com

Read more on the Reapplix website



Reapplix Aps
Blokken 45, 3460 Birkerød, Denmark

You received this e-mail because you applied for our newsletter or
are on our mailing list

Like

Share

Forward

[Preferences](#) | [Unsubscribe](#)